Nimble Therapeutics is bringing the power of massively parallel chemical synthesis to drug discovery.
Acquired by AbbVie in 2025.
Nimble Therapeutics is bringing the power of massively parallel chemical synthesis to drug discovery.
Acquired by AbbVie in 2025.
This website uses cookies and similar technologies to support basic site functionality and help us understand how visitors use the site. We use analytics tools such as Google Analytics, to improve website performance and content.We do not sell personal information or use cookies for targeted advertising.You can accept all cookies, reject non-essential cookies, or adjust your preferences at any time. For more information, please review our Privacy Policy.
Some required resources have been blocked, which can affect third-party services and may cause the site to not function properly.
This website uses cookies to enhance your browsing experience and ensure the site functions properly. By continuing to use this site, you acknowledge and accept our use of cookies.